Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -180.51% is 39% below its 1-year average of -129.75%, near the low end of its 1-year range (-180.51%–-79.00%).
As of the fiscal period ended Wednesday, December 31, 2025. 39.12% below its 12-month average of -129.75%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.46%.
RETURN ON ASSETS (ROA)
-180.51%
RETURN ON ASSETS (ROA) AVG TTM
-129.75%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-39.12%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.81%
median of 841 covered companies
CURRENT VS SECTOR MEDIAN
-467.46%
vs the sector median at left
Parabilis Medicines, Inc.
Market Cap
$3.33B
Return on Assets (ROA)
-180.51%
TTM Avg
-129.75%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.35B
Return on Assets (ROA)
-102.47%
TTM Avg
-31.18%
3Y Avg
-31.63%
5Y Avg
-28.00%
Market Cap
$3.38B
Return on Assets (ROA)
20.83%
TTM Avg
2.76%
3Y Avg
-12.34%
5Y Avg
-9.97%
Market Cap
$3.39B
Return on Assets (ROA)
-69.27%
TTM Avg
-58.09%
3Y Avg
-65.66%
5Y Avg
-83.41%
Market Cap
$3.40B
Return on Assets (ROA)
21.83%
TTM Avg
22.04%
3Y Avg
-0.21%
5Y Avg
-10.13%
Market Cap
$3.19B
Return on Assets (ROA)
-7.60%
TTM Avg
-21.23%
3Y Avg
-30.23%
5Y Avg
-24.04%
Market Cap
$3.47B
Return on Assets (ROA)
-13.36%
TTM Avg
-17.34%
3Y Avg
-16.80%
5Y Avg
-15.30%
Market Cap
$3.48B
Return on Assets (ROA)
-27.35%
TTM Avg
-41.78%
3Y Avg
-34.97%
5Y Avg
-41.24%
Market Cap
$3.48B
Return on Assets (ROA)
-11.52%
TTM Avg
-33.33%
3Y Avg
-29.18%
5Y Avg
-25.57%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.33B | -180.51% | -129.75% | N/A | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.35B | -102.47% | -31.18% | -31.63% | -28.00% |
| CareDx, Inc (CDNA)vs › | $3.38B | 20.83% | 2.76% | -12.34% | -9.97% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.39B | -69.27% | -58.09% | -65.66% | -83.41% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.40B | 21.83% | 22.04% | -0.21% | -10.13% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -7.60% | -21.23% | -30.23% | -24.04% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.47B | -13.36% | -17.34% | -16.80% | -15.30% |
| Celcuity Inc. (CELC)vs › | $3.48B | -27.35% | -41.78% | -34.97% | -41.24% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.48B | -11.52% | -33.33% | -29.18% | -25.57% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.48B | -31.58% | -32.30% | -25.03% | -21.53% |
ROA
-180.5%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -180.51% |
| 2024-12-31 | -79.00% |
